Table 1.
Summary of the main characteristics and findings of studies describing long-term kidney function loss in TDF-treated patients.
| Variable | United States | Australia | Germany |
|---|---|---|---|
| Study type | Longitudinal cohort | Retrospective cohort | Retrospective cohort |
| Treated patients (n) | 344 | 290 | 82 |
| Controls (n) | 314 | 618 | 92 |
| Age (yr)a | |||
| Cases | 38 (34–43) | 46 (23 to 38) | 42.6±8.1 |
| Controls | 32 (32–45); NS | 45 (21 to 75); NS | 42.3±8.4; NS |
| CD4 count (cells/mm3)a | |||
| Cases | 220 (77–433) | 460 (425 to 496) | 501±267 |
| Controls | 210 (94–380); NS | 523 (499 to 547); NS | 571±266; NS |
| Average treatment duration (mo)b | 9.9 (5.5, 12.0) | 20.4 (18.0 to 21.6) | 9±7.3 months |
| Change in kidney function | −13.3 ml/min (cases) versus −7.5 ml/min (controls); P=0.005 | −5.6 ml/min (cases) versus 1.3 ml/min (controls); P=0.002 | 97±49 ml/min (cases) versus 107±39 ml/min (controls); P<0.05 |
| Kidney function assessment | Cockcroft-Gault | Cockcroft-Gault indexed to ideal body weight | Measured creatinine clearance |
| Reference | 35 | 36 | 37 |
NS, not significant.
a
Values for United States are median (first–third quartile); values for Australia are mean (95% confidence interval); values for Germany are mean ± SD.
b
Values for United States are mean (minimum, maximum); values for Australia are mean (95% confidence interval); values for Germany are mean ± SD.